This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AngioDynamics (ANGO) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
AngioDynamics (ANGO) is optimistic about maintaining its robust product portfolio.
Masimo's (MASI) Wearable Wireless Thermometer Gets FDA Nod
by Zacks Equity Research
Masimo's (MASI) continuous, wearable thermometer is likely to help monitor and track body temperature in all thermometer applications following the FDA's clearance.
NEOGEN's (NEOG) Soleris Test to Serve the Cannabis Industry
by Zacks Equity Research
NEOGEN's (NEOG) Soleris Direct Yeast and Mold test is approved by the AOAC Institute to identify yeasts and molds in dried cannabis flower.
OPKO Health (OPK) Inks Agreement to Sell Its Ireland Facility
by Zacks Equity Research
OPKO Health (OPK) expects to improve its business efficacy and focus on oral solid dose products post the sale of its Ireland facility.
ResMed (RMD) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) on solid digital health growth potential along with rising demand for masks and other accessories.
CVS Health (CVS) Digital Tools Gain Steam Amid COVID-19 Crisis
by Zacks Equity Research
CVS Health's (CVS) consumer-centric digital strategy is more relevant in the current environment as people are increasingly using technology while staying indoors.
Here's Why You Should Add DaVita (DVA) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DaVita (DVA) on its slew of tie-ups and strength in its kidney care business.
Bruker (BRKR) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Bruker (BRKR) on solid CALID Group growth potential and raised 2021 financial guidance.
AMN Healthcare (AMN) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
AMN Healthcare (AMN) is optimistic about maintaining its strength in staffing service as well as offering a broad array of services.
Masimo's (MASI) ORi-Guided OLV Procedure Favored by New Study
by Zacks Equity Research
Masimo's (MASI) ORi-guided thoracic anesthesia procedure is likely to reduce hospital stay and increase patient safety.
Reasons to Add HealthEquity Stock (HQY) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity (HQY) on its slew of buyouts and strength in HSA.
Dexcom's (DXCM) G6 CGM System Gets Coverage in British Columbia
by Zacks Equity Research
Dexcom's (DXCM) CGM is expected to simplify diabetes management due to increasing access to the life-changing technology.
Philips (PHG) Recalls CPAP, Ventilators Used for Sleep Apnea
by Zacks Equity Research
Philips (PHG) is recalling some Bi-Level PAP, CPAP, and mechanical ventilator devices in the United States due to health risks.
Accuray (ARAY) Expands Commercialization of CE-Marked ClearRT
by Zacks Equity Research
Accuray's (ARAY) ClearRT imaging capability, which is now widely available following receipt of the CE Mark, offers better precision and accuracy in radiation therapy.
The Zacks Analyst Blog Highlights: National Vision, DaVita, Elanco Animal Health, Henry Schein and Phibro Animal Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: National Vision, DaVita, Elanco Animal Health, Henry Schein and Phibro Animal Health
5 Probable MedTech Winners Post-COVID on Discounted PEG
by Zacks Equity Research
Here are some MedTech stocks with favorable PEG ratio, which are expected to provide gains in 2021.
The Zacks Analyst Blog Highlights: National Vision Holdings, Maravai LifeSciences, Sonova Holding, Sartorius and Henry Schein
by Zacks Equity Research
The Zacks Analyst Blog Highlights: National Vision Holdings, Maravai LifeSciences, Sonova Holding, Sartorius and Henry Schein
Bruker (BRKR) FluoroType Assay Detects New SARS-CoV-2 Variants
by Zacks Equity Research
Bruker's (BRKR) FluoroType SARS-CoV-2 varID Q assay differentiates and quantifies the SARS-CoV-2 virus in just one PCR test, thereby reducing workload, cost, and time.
5 MedTech Stocks to Gain in 2021 as Base Business Recovers
by Urmimala Biswas
These five MedTech stocks, EYE, MRVI, SONVY, SARTF and HSIC, all with a favorable Zacks Rank and growth parameters are expected to put up a robust performance in 2021.
Brokers Like These Growth Stocks, and So Do We
by Sejuti Banerjea
One way to make money from the stock market is by following the experts.
Here's Why You Should Retain LHC Group (LHCG) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about LHC Group (LHCG) owing to its slew of buyouts and a broad array of services.
Baxter's (BAX) Theranova-Enabled HDx Therapy Data Positive
by Zacks Equity Research
Baxter's (BAX) Theranova-enabled HDx therapy is likely to boost clinical outcomes and lower healthcare resource utilization.
Medtronic's (MDT) STROKE AF Trial Outcome Backs ICM Progress
by Zacks Equity Research
STROKE AF trial shows Medtronic's (MDT) Reveal LINQ ICM has a seven-fold advantage in detecting AF compared to traditional standard of care in patients with large vessel or small vessel stroke.
Why You Should Add Veeva Systems (VEEV) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of partnerships and robust product adoptions.
Cooper Companies (COO) Q2 Earnings Top Estimates, '21 View Up
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter 2021 earnings reflect solid segmental performance.